Enliven Therapeutics files Section 144 for 45,000 shares

Enliven Therapeutics, Inc. filed a Section 144 notice reporting proposed and recent sales of Common Stock by an affiliate through Jefferies LLC.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. filed a Section 144 notice reporting proposed and recent sales of Common Stock by an affiliate through Jefferies LLC.

The filing lists a proposed sale of 45,000 shares with a related value of $1,401,750.00 and trade/broker details noting Nasdaq and a filing date of 03/25/2026. The filing also discloses prior sales by Helen Collins of 45,000, 29,871, 10,129, and 5,000 shares on 02/17/2026, 03/09/2026, 03/10/2026, and 03/17/2026 respectively, with the dollar amounts shown for each transaction.

Insights

Equity Capital Markets Analyst

Section 144 notice shows affiliate sales and a proposed 45,000-share offering via Jefferies.

The filing lists a proposed sale of 45,000 Common shares with a related amount of $1,401,750.00 and identifies Jefferies LLC as the broker. It records earlier sales by Helen Collins across four dates totaling disclosed proceeds.

Cashflow treatment and any trading method beyond brokered transactions are not detailed; subsequent Form 4/144 updates could state actual execution details or method changes.

Corporate Governance Specialist

Affiliate disposition is recorded; filings document both proposed and prior executed sales.

The notice ties multiple executed sales by Helen Collins to specific dates and gross proceeds, providing a clear historical trace of disposals. The proposed sale is routed through Jefferies, listed with a Nasdaq execution context.

Compliance watchers should expect any final sale confirmations or Rule 144 eligibility statements in follow-up filings; the excerpt does not state holding-period or resale-limitation qualifiers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 04:29 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001701247
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Collins Helen Louise
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	45000	1401750.00	59000000	03/25/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock Options	Enliven Therapeutics Inc.			45000	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Collins 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics, Inc.	02/17/2026	45000	1177863.50
Helen Collins 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics, Inc.	03/09/2026	29871	896809.86
Helen Collins 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics, Inc.	03/10/2026	10129	305826.52
Helen Collins 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics, Inc.	03/17/2026	5000	138799.90

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 10/19/2025, and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	03/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Helen Collins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)